Skip to main content
. 2019 Jun 5;60(5):630–638. doi: 10.1093/jrr/rrz040

Table 1.

Patient characteristics

Characteristics Total Patients aged ≥65 years
Non-PCIa (n = 95) PCIa (n = 139) P-value Non-PCIa (n = 35) PCIa (n = 33) P-value
Gender 0.469 0.651
 Male 81 (85.3) 123 (88.5) 31 (88.57) 28 (84.85)
 Female 14 (14.7) 16 (11.5) 4 (11.43) 5 (15.15)
Age 0.030 -
 <65 years 60 (63.2) 106 (76.3)
 ≥65 years 35 (36.8) 33 (23.7)
 Median (range) 62 years 60 years 67 years 68 years
(40–77) (34–75) (65–77) (65–75)
LDH 0.006 0.041
 <400 U/l 34 (36.6) 76 (55.1) 10 (28.6) 17 (53.1)
 ≥400 U/l 59 (63.4) 62 (44.9) 25 (71.4) 15 (46.9)
 Median (range) 459 U/l 388 U/l 470 U/l 391 U/l
(237–1402) (224–1078) (269–758) (237–927)
Performance Status 0.054 0.594
 0 7 (7.4) 22 (15.8) 2 (5.7) 3 (9.1)
 1–2 88 (92.6) 117 (84.2) 33 (94.3) 30 (90.9)
cT 0.565 0.242
 0–2 80 (84.2) 113 (81.3) 32 (91.4) 27 (81.8)
 3–4 15 (15.8) 26 (18.7) 3 (8.6) 6 (18.2)
cN 0.274 0.346
 0–1 20 (21.1) 38 (27.3) 10 (28.6) 13 (39.4)
 2–3 75 (78.9) 101 (72.7) 25 (71.4) 20 (60.6)
Stage 0.543 0.492
 I–II 20 (21.1) 34 (24.5) 10 (28.6) 12 (36.4)
 III 75 (78.9) 105 (75.5) 25 (71.4) 21 (63.6)
Tumor volume 0.337 0.270
 <50 ml 15 (21.7) 50 (51.0) 8 (47.1) 15 (55.6)
 ≥50 ml 21 (58.3) 48 (49.0) 9 (52.9) 12 (44.4)
 Median (range) 53.1 ml 48.5 ml 53.2 ml 45.0 ml
(21.8–139.8) (11.4–172.4) (21.8–115.9) (11.4–146.4)
Radiotherapy dose <0.001 0.001
 44 Gy 62 (65.3) 39 (28.1) 21 (60.0) 7 (21.2)
 52.5 Gy 33 (34.7) 100 (71.9) 14 (40.0) 26 (78.8)
Treatment schedule 0.004 0.475
 Early 71 (74.7) 78 (56.1) 20 (57.1) 16 (48.5)
 Late 24 (25.3) 61 (43.9) 15 (42.9) 17 (51.5)

PCI = prophylactic cranial irradiation, LDH = lactate dehydrogenase, U/l = units per liter.

aValues are numbers (%).